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Summary 
Background Hodgkin’s lymphoma is one of the most common lymphoid neoplasms in young adults, but 
the low abundance of neoplastic Hodgkin/Reed-Sternberg cells in the tumour hampers the elucidation of 
its pathogenesis, biology, and diversity. After an incidental observation that genomic aberrations known 
to occur in Hodgkin’s lymphoma were detectable in circulating cell-free DNA, this study was undertaken to 
investigate whether circulating cell-free DNA can be informative about genomic imbalances in Hodgkin’s 
lymphoma. 
 
Methods We applied massive parallel sequencing to circulating cell-free DNA in a prospective study of 
patients with biopsy proven nodular sclerosis Hodgkin’s lymphoma. Genomic imbalances in Hodgkin/Reed-
Sternberg cells were investigated by fluorescence in-situ hybridisation (FISH) on tumour specimens. 
 
Findings By non-invasive prenatal testing (NIPT), we observed several genomic imbalances in circulating 
cell-free DNA of a pregnant woman, who was subsequently diagnosed with early-stage nodular sclerosis 
Hodgkin’s lymphoma stage IIA during gestation. FISH on tumour tissue confirmed corresponding genomic 
imbalances in Hodgkin/Reed- Sternberg cells. We prospectively studied circulating cell-free DNA of nine 
nodular sclerosis Hodgkin’s lymphoma cases: eight at first diagnosis and one at first relapse. Seven 
patients had stage IIA disease and two had stage IVB disease. In eight, genomic imbalances were 
detected, including, among others, gain of chromosomes 2p and 9p, known to occur in Hodgkin’s 
lymphoma. These gains and losses in circulating cell-free DNA were extensively validated by FISH on 
Hodgkin/Reed-Sternberg cells in biopsy samples. Initiation of chemotherapy induced normalisation of 
circulating cell-free DNA profiles within 2–6 weeks. The cell cycle indicator Ki67 and cleaved caspase-
3 were detected in Hodgkin/Reed-Sternberg cells by immunohistochemistry, suggesting high turnover of 
Hodgkin/Reed-Sternberg cells. 
 
Interpretation In early and advanced stage nodular sclerosis Hodgkin’s lymphoma, genomic imbalances in 
Hodgkin/ Reed-Sternberg cells can be identified by massive parallel sequencing of circulating cell-free DNA 
at diagnosis. The rapid normalisation of circulating cell-free DNA profiles on therapy initiation suggests a 
potential role for circulating cell-free DNA profiling in early response monitoring. This finding creates several 
new possibilities for exploring the diversity of Hodgkin’s lymphoma, and has potential implications for the 
future clinical development of biomarkers and precision therapy for this malignancy. 
 
Funding: KU Leuven - University of Leuven and University Hospitals 
Leuven. 
  
Introduction 
Hodgkin’s lymphoma accounts for 11-30 % of all lymphomas and is the most common lymphoid neoplasm 
in adolescents and young adults. With the development of chemotherapy with or without radiotherapy in 
the past five decades, Hodgkin’s lymphoma is highly curable today. However, 10-15% of patients will fail 
first-line therapy and will require salvage therapy, while a similar proportion is likely to be overtreated by 
first-line therapy.1-3 
Remarkably, much of the therapeutic advances in Hodgkin’s lymphoma took place without thorough 
knowledge of the origin and biology of the Hodgkin/Reed-Sternberg cell, the malignant cell in classical 
Hodgkin’s lymphoma (classical Hodgkin’s lymphoma). A salient feature of Hodgkin/Reed-Sternberg cells 
is their low abundance in biopsy samples, where they usually represent only 0·1-2% of the tumour mass, 
while the remainder is composed of a mixture of non-malignant immune cells. This has been a major 
obstacle in the study of the biology and genetics of classical Hodgkin’s lymphoma, leading researchers to 
study Hodgkin/Reed-Sternberg cell-derived cell lines, or, more recently, Hodgkin/Reed-Sternberg cells 
captured by laser microdissection.2-8 
In the past decade, the interest in circulating cell-free DNA has risen steeply in many medical 
disciplines.9 The presence of fetal DNA fragments in plasma from pregnant women is the principle 
underlying non-invasive prenatal testing . Non-invasive prenatal testing is becoming widely implemented, 
either with assays targeting trisomies 13, 18 and 21, or by massive parallel sequencing, which also allows 
genome-wide detection of fetal aneuploidies and segmental imbalances 10. In patients with cancer, 
circulating cell-free DNA may contain tumour-derived DNA, and hence be informative about the tumour 
genome. For instance, massive parallel sequencing on circulating cell-free DNA can reveal genome-wide 
tumour-associated copy number profiles.11-13 In addition, Thierry and colleagues demonstrated that 
analysis of KRAS and BRAF mutation status on circulating cell-free DNA in metastatic colorectal cancer is 
highly specific and sensitive.14 The analysis of circulating tumour DNA may also find other promising 
applications, such as early tumour detection, assessment of molecular disease heterogeneity, monitoring 
of response, detection of minimal residual disease, and molecular evolution and emergence of resistance. 
9 
We recently implemented a novel non-invasive prenatal testing pipeline based on massive parallel 
sequencing of circulating cell-free DNA in pregnant women for prenatal testing15. The discovery of a patient 
with a complex circulating cell-free DNA profile due to early stage nodular sclerosis Hodgkin’s lymphoma 
led us to investigate whether circulating cell-free DNA would be a useful tool to study the genetics of the 
disease.  
 
METHODS 
Participants 
Ten patients in total were included in this study. The first blood sample of patient unique patient number 
(UPN)01 was obtained in the context of non-invasive prenatal testing. Subsequent patients with nodula 
sclerosis Hodgkin’s lymphoma were recruited between April 29 2014, and July 2, 2014, at the University 
Hospital Leuven, in a prospective study that assessed the detection of genomic imbalances in nodular 
sclerosis Hodgkin‘s lymphoma in circulating cell-free DNA at diagnosis and during therapy. Patients 
included were aged older than 12 years, had nodular sclerosis Hodgkin’s lymphoma at first diagnosis 
or at relapse, had available of biopsy materials (cytogenetic specimens, fresh frozen or formalin-
fixed paraffin embedded sections), and absence of concomitant malignancies. The study was approved 
by the Institutional Review Board of the University Hospitals Leuven, Belgium (Belgian number 
B32220141013, Study S56534/ML10468, date of approval 29/04/2014), and all participants provided 
written informed consent. 
 
 
Genomic representation profiling  
Blood was obtained in Cell-Free DNA BCT tubes (Streck, Omaha, NE, USA), and circulating cell-free 
DNA extracted from 4–5 mL of plasma. Sequencing libraries were prepared with the TruSeq Chip 
Sample preparation kit (Illumina, San Diego, CA, USA), indexed, and analysed by multiplex 
sequencing across both lanes of an Illumina HiSeq2500 (fast mode producing 50 bp single- end reads 
in pools of 23–24 samples). 
The sequence reads were aligned to the reference genome with the Burrows-Wheeler aligner, de-
duplicated with Picard instrument, and realigned and recalibrated with Genome Analysis Toolkit 
(GATK). Reads were removed that match (suboptimally) at multiple locations, require mismatches or 
gaps in the alignment, or start in blacklisted regions taken from an in-house curated list of common 
polymorphic copy-number variants, collapsed repeats, DAC blacklisted regions generated for the 
Encyclopedia of DNA elements (ENCODE) project, and the undefined portion of the reference 
genome. Thus, a minimum of 7·9 × 10⁶ reads (mean 10·3 × 10⁶ were obtained, corresponding to a 
minimum of roughly 11·3 × 10⁶ raw reads (mean 14·5 × 10⁶).15 
The aligned and filtered reads were counted as described. Normalisation was done with respect to 
the autosomes. We partitioned all autosomes into 50 kb bins, corrected the sequence counts with 
LOESS regression according to the bin GC content, and divided the result by the sum of autosomal 
sequence counts, yielding t bin GC-corrected genomic representations. These were aggregated per 
autosome and per window representing 1/10th partitions of the chromosome, for which the windows 
are shifting by 50 kb. Z-scores for the genomic representation were calculated with mean and SD of 
genomic representations values from a reference set of 100 normal samples (50 men [46,XY], 50 
women [46,XX] pregnancies). Z-scores greater than 1·5 and less than –1·5 suggested gain or gain 
or loss, respectively,15 (for detailed description and references see appendix pp 2–3) 
 
 
Array comparative genomic hybridisation (aCGH) and FISH 
aCGH was done with 60k CytoSure ISCA v2 microarray, and analysed with CytoSure Interpret Software 
x
(Oxford Gene Technology OGT, Oxford, UK). FISH was done on fixed cells from cytogenetic cultures, or 
on 5 µm sections of FFPE or snap-frozen biopsies following standard procedures. Combined 
FISH/CD30 immunostaining was done on 5 µm sections from snap-frozen biopsies. FISH images 
were acquired with a fluorescence microscope with an Axiophot2 camera (Carl Zeiss Microscopy, 
Jena, Germany) and ISIS software (MetaSystems, Altlussheim, Germany). Detailed methods and DNA 
probes are described in the appendix pp 3–4. 
 
Immunohistochemistry and imaging 
FFPE tissue sections were stained automatically (DAKO, Carpinteria, CA, USA). Antibodies against Ki67 
(MIB1, DAK0, Glostrup, Denmark) and against cleaved caspase-3 (Ab2302, Abcam, Cambridge Science 
Park, Boston, MA, USA) were used as ready to use or at 1:50 dilution, respectively. Two expert 
independent observers counted Hodgkin/Reed-Sternberg cells in five representative high-power fields 
each. The percentage of Ki67-positive Hodgkin/Reed-Sternberg cells was estimated by visual interpretation 
of the immunohistochemical stain taking into account the presence of Ki67-positive small lymphocytes 
and larger histiocytes, in correlation with the cellular detail and distribution of the corresponding 
haematoxylin-eosin stain, CD30 immunostain, and the blue counterstain. 
Routine classical Hodgkin’s lymphoma staging and follow-up imaging was with FDG-PET/CT 
(UPN01–03 and UPN06–10) or CT (UPN04–05), or both.16 During pregnancy, UPN01 was assessed 
by whole body diffusion- weighted MRI, a radiation and contrast medium free imaging modality 
(according to the protocols in clinical studies NCT00330447 and NCT01231269).17 
 
Statistical analysis 
Observed proportions and 95% exact (Clopper-Pearson) lower confidence limits are reported. 
Computations were done with the SAS, version 9.3. 
 
Role of the funding source 
The funders were not involved in the study design, data collection, data analysis, and data interpretation, 
or the writing of the report. All authors had full access to all of the data. PV had the final responsibility 
to submit for publication. 
 
 
RESULTS 
After analysis of more than 1000 cases with a recently implemented NIPT pipeline, a test on 
circulating cell-free DNA from a 27-year-old asymptomatic pregnant woman (UPN01) at 12-weeks 
gestational age yielded a markedly abnormal genomic representation profile. According to local 
guidelines, a second circulating circulating cell-free DNA sample was obtained and analysed 2 weeks 
later with a similar result (figures 1, 2, appendix p 5), thus excluding poor quality of the sample 
and the sequencing process. Therefore, suspecting a biological reason for the aberrant profile, 
amniocentesis was done followed by aCGH and conventional karyotyping on amniotic cells: both 
indicated a normal diploid fetal genome (data not shown). The pregnant mother also had a normal 
diploid genome, as shown by aCGH on her lymphocytes (data not shown). Hence, a malignant 
disorder in mother or fetus, with somatically acquired genomic imbalances, was considered. A fetal 
tumour was excluded by expert fetal ultrasound, but whole body diffusion-MRI of the mother showed a 
confluent anterior mediastinal mass and several pathologically enlarged lymph nodes in the left 
lower cervical and bilateral retroclavicular regions, without involvement elsewhere. A CT-guided 
puncture biopsy of the mediastinal mass revealed a nodular sclerosis Hodgkin’s lymphoma on 
pathological examination. aCGH on whole DNA from the biopsy sample showed a normal diploid 
pattern, as expected due to the rarity of Hodgkin/Reed-Sternberg cells (data not shown). Therefore, in 
search of genomic imbalances in Hodgkin/Reed-Sternberg cells, we 1 resorted to FISH analysis of FFPE 
biopsy sections. Three regions gained in the genomic representations profile, 8q terminal (ter), 9pter, 
and 14q, were examined with probes for MYC (8q24), JAK2 (9p24), and IGH (14q32; 5 figure 1). The 
JAK2 probe was applied together with a probe for centromere (CEP) 8, as ploidy control. Hodgkin/Reed-
Sternberg cells showed three to four MYC signals, two CEP8 signals, one to two clusters of amplified 
JAK2 signals in addition to two normal signals, 10 and four IGH signals (table). By contrast, normal 
patterns were noted in neighbouring cells (figure 1). Assuming a hyperdiploid status of Hodgkin/Reed- 
Sternberg cells in this case, the genomic gains in circulating cell-free DNA match with gains of the 15 
corresponding chromosomal regions in Hodgkin/Reed- Sternberg cells, as shown by FISH. This strongly 
suggests that circulating cell-free DNA from UPN01 contains DNA representative of Hodgkin/Reed 
Sternberg cells. We hypothesised that aberrant genomic representation profiles in circulating cell-free DNA 
could be recurrent in nodular sclerosis Hodgkin’s lymphoma. Therefore, circulating cell-free DNA was 
prospectively obtained from cases UPN02–10, consecutively diagnosed in our hospital with newly 
diagnosed nodular sclerosis Hodgkin’s lymphoma (UPN02–04, UPN06–10) or with nodular sclerosis 
Hodgkin’s lymphoma in first relapse (UPN05). Seven cases had supradiaphragmatic stage IIA disease 
and two had stage IVB disease (table). 
Figure 2 shows a composite plot of the diagnostic genomic representations profiles of all patients, 
including UPN01. As in patient UPN01, the profiles of cases UPN03, UPN07, UPN08, UPN09, and 
UPN10 revealed substantial imbalances affecting several chromosomes or chromosomal arms, 
whereas in patients UPN04–06 fewer and less pronounced imbalances were noted. No obvious 
abnormalities were identified in patient UPN02 (figure 2) The most frequently affected regions, with 
gains seen in five or more patients, were 2p (n=7), 3q, 5p, and 9p/9pter (n=5). Other regions with gains in 
three or four patients included 8q/8qter, chromosome 12, and chromosome 19 (n=4), and 1q, 2q, 5q, 
chromosome 14, and 17q (n=3). Loss of 1p, 6q, 7q/qter, 9qter, 10q, 11qter, 13q, and 22q were noted in 
four or five patients, and loss of chromosome 4, 17p, chromosome 18 and 20p were each seen in three 
patients (figure 2).  
To verify genomic representation profiles, all Hodgkin/ Reed-Sternberg cells that could be identified 
morphologically were extensively evaluated by FISH on cytogenetic specimens (table, figure 3). We 
noted a striking overall concordance between genomic imbalances in circulating cell-free DNA and 
altered copy numbers of the corresponding chromosomal regions in nearly all FISH experiments. For 
instance, the genomic representations profile of UPN08 indicated loss of 7q, nd gain of 1q, 2p, 7p, 
and 9p (excluding 9p24). These regions were explored by interphase FISH on cytogenetic specimens, 
with probes for CKS1B (1q21)/CEP1, ALK (2p23), TCRG (7p14)/CEP7, D7S486 (7q31)/CEP7, and 
JAK2 (9p24)/CEP8. Giant cells displayed three CKS1B signals versus two CEP1 signals, five to 11 
signals for ALK, and three to four signals for TCRG versus two to three CEP7 signals. They also showed 
two to four signals. FISH thus confirmed gain of 1q, 2p, and 7p and loss of 7q (figure 3B– D, table). To 
identify the cells with abnormal hybridization patterns with certainty, we combined FISH for 2p24 MYCN) 
with CD30 immunostaining on the snap-frozen biopsy of UPN08. The giant cells with additional 2p24/ 
MYCN signals were CD30-positive, identifying them unequivocally as Hodgkin/Reed-Sternberg cells. 
Neighbouring cells with normal patterns were CD30- negative (figure 3F). Of note, the giant cells often 
displayed more than two centromeric signals for chromosomes 1, 7, or 8: this reflects the frequently 
polyploid and multinucleated state of Hodgkin/Reed- 15 Sternberg cells.18 Additionally, several 
hybridisation patterns in the giant cells were often observed within experiments, consistent with the 
known subclonal variation of Hodgkin/Reed-Sternberg cells:19 for instance, FISH for 9p24 in UPN08 
showed a balanced pattern in 20 three cells and gain in three others, yielding only partial concordance 
with the genomic representations profile for 9p (figure 3E, table). The small surrounding non- malignant 
cells exhibited homogeneously normal hybridisation patterns. 
FISH for ALK (2p23) indicated gain in UPN03–10, while UPN02 was confirmed to have two copies (table, 
figure 3G), consistent with genomic representations profiling in all but one case (UPN06). For D7S486 
(7q31), FISH and genomic representations profiling were concordant in all cases tested. For JAK2 (9p24), 
FISH was in agreement with genomic representation profiling in UPN01–03 and UPN05–07. For UPN08–09, 
partial concordance was noted, again due to subclonal variation (table, figure 3A, G, H). UPN04 and UPN10 
were discordant, with gain in FISH espite, respectively, a balance or loss in the genomic representations 
profile for 9p/9pter (table). Hence, with only three discordances in total, we noted a striking overall 
agreement between the genomic imbalances in circulating cell-free DNA by genomic representations 
profiling and those in Hodgkin/Reed-Sternberg cells identified by FISH. This cogently demonstrates that 
circulating cell-free DNA contains DNA derived from and representative of Hodgkin/Reed-Sternberg cells.  
 genomic representation profile aberrations were most pronounced in cases UPN08–09, each with stage 
IVB disease. This suggests a correlation between tumour load and Hodgkin/Reed-Sternberg cell-derived 
DNA in the circulating cell-free DNA. Nevertheless, genomic representation profiling also allowed detection 
of several aberrations in UPN03–07 and UPN10 with nodular sclerosis Hodgkin’s lymphoma stage IIA, 
although some gains (2p23 in UPN06, and 9p24 in UPN04 and UPN10) were not correctly identified 
(table). Based on eight positive results out of nine prospectively recruited cases, the 95% ower limit for the 
proportion of positive samples equals 57%, implying strong evidence for abnormal circulating cell-free 
DNA profiles in a substantial proportion of nodular sclerosis Hodgkin’s lymphoma cases. 
All patients, including the pregnant patient, were treated with combination doxorubicin, bleomycin, 
vinblastine, and dacarbazine chemotherapy with or without involved node radiotherapy, except 
UPN04–05 who were treated according to EuroNet-PHL recommendations. All responded as shown 
by early clinical evaluation. At the first interim PET/CT imaging evaluation after two to four cycles of 
chemotherapy, patients UPN01–04 and UPN06–10 all had reached complete metabolic remission. 
Patient UPN05 reached partial remission at the first interim evaluation by CT evaluation after four 
cycles and complete metabolic remission by PET and CT at the completion of chemotherapy. The 
abnormalities in the genomic representations profile at diagnosis were no longer observed in subsequent 
samples taken between day 15–43 after treatment initiation (figure 4, appendix p xx. This, in combination 
with the clinical disease response, further underscores the link between the abnormal genomic 
representations profiles and the malignant process and its burden. Furthermore, it suggests that early 
responses can be monitored non- invasively. 
The ease by which Hodgkin/Reed-Sternberg DNA is detectable in circulating cell-free DNA contrasts 
with the paucity of Hodgkin/Reed-Sternberg cells in classical Hodgkin’s lymphoma biopsies. We 
hypothesised that high Hodgkin/Reed-Sternberg cell turnover rates could be a key factor underlying this 
paradox. In general, Hodgkin/Reed-Sternberg cells showed bright nuclear expression of the cell cycle 
indicator Ki67 in all ten cases, with immunoreactivity ranging between 30–90% (median 80% [IQR 65–
82]) of Hodgkin/Reed-Sternberg cells in individual patients. In addition to morphological signs of 
apoptosis, immunoreactivity with the anti- cleaved caspase-3 antibody was noted in a fraction of 
Hodgkin/Reed-Sternberg cells in six out of ten biopsies. Of note, areas of tissue necrosis were observed in 
two of the biopsies (figure 5). 
 
Discussion 
The scarcity of Hodgkin/Reed-Sternberg cells in classical Hodgkin’s lymphoma biopsy samples has for a 
long time defied the identification of recurrent genetic lesions in classical Hodgkin’s lymphoma, 
including nodular sclerosis Hodgkin’s lymphoma.2–8 Here, we report proof of-principle that genomic 
imbalances in Hodgkin/Reed- Sternberg cells can be profiled at diagnosis by massive parallel 
sequencing of circulating cell-free DNA in most cases with early and advanced stage nodular 
sclerosis Hodgkin’s lymphoma. Of note, increased levels of circulating cell-free DNA were previously 
reported in classical Hodgkin’s lymphoma, and correlated with unfavourable features. However, the 
origin of this circulating cell-free DNA was not further investigated.20,21 This study is, to the best of our 
knowledge, the first to show that genomic imbalances of Hodgkin/Reed-Sternberg cells can be detected in 
circulating cell-free DNA (panel). The straightforward identification is unexpected but welcome, in 
that retrieving genetic information about Hodgkin/Reed- Sternberg cells from Hodgkin’s lymphoma 
biopsy samples is notoriously demanding from a technical point of view. Indeed, the present knowledge 
of the genetics of Hodgkin/Reed-Sternberg cells is almost entirely derived from a small number of 
studies of Hodgkin’s lymphoma cell lines, and of microdissected Hodgkin/Reed- ternberg cells, after 
whole genome DNA amplification.4–8 Reassuringly, the imbalances identified in this study of ten 
nodular sclerosis Hodgkin’s lymphoma have previously been observed in aCGH studies on 1 
microdissected Hodgkin/Reed-Sternberg cells, albeit with different frequencies.4–8 Interestingly, we also 
confirm that 2p gain and 6q loss often occur together.8 We also noted gain of 16p11–13, previously 
identified in 5 25% of classical Hodgkin’s lymphoma, and associated with therapy resistance,8 in two 
cases with stage IVB. The presence of informative amounts of Hodgkin/ Reed-Sternberg cell derived DNA 
in circulating cell-free DNA, despite their scarcity in classical Hodgkin’s 10 lymphoma biopsy samples, 
probably implies that Hodgkin/Reed-Sternberg cells are subject to a higher cellular turnover rate than 
previously anticipated. Although we studied one proliferative and one apoptotic marker only, their 
coexpression on Hodgkin/Reed-Sternberg cells and the presence of necrosis in classical Hodgkin’s 
lymphoma biopsy samples seem to support the notion that active proliferation is counterbalanced by 
high amounts of Hodgkin/Reed-Sternberg cell loss by apoptosis or necrosis, in keeping with expression 
studies 20 in Hodgkin/Reed-Sternberg cells.22,23 This delicate balance might also explain the high 
efficacy of chemotherapy, because Hodgkin/Reed-Sternberg cells are already poised for cell death. 
genomic representations profiles were most greatly abnormal in in the two patients (UPN08–09) with 
advanced disease, suggesting an association between the Hodgkin/ Reed-Sternberg cell burden and the 
level of Hodgkin/ Reed-Sternberg cell derived DNA in circulating cell-free DNA. However, seven of eight 
patients with early stage IIA (including patient UPN01) had abnormal profiles too. On the basis of the 
high proportion of abnormal genomic representations profiles in this small series, a substantial, if not the 
major, proportion of cases with nodular sclerosis Hodgkin’s lymphoma is expected to have abnormal 
circulating cell-free DNA profiles. Larger studies are needed to precisely determine the sensitivity 
of this technique in classical Hodgkin’s lymphoma, in relation with the disease stage. These larger 
studies should also nclude the mixed cellularity, lymphocyte-rich, and lymphocyte-depleted subtypes of 
classical Hodgkin’s lymphoma, and nodular lymphocyte predominant Hodgkin’s lymphoma, less common 
types of Hodgkin’s lymphoma, which were not included in this study. 
The relation between the burden of Hodgkin/Reed- Sternberg cells and the abnormal genomic 
representation profiles is also underscored by the rapid clearance of genomic representation 
abnormalities present at diagnosis after the initiation of therapy. In view of this rapid clearance, genomic 
representation profiling seems 50 in the patterns of genomic imbalances. Again, larger unlikely to 
have great potential to sensitively monitor low levels of residual disease, even more so as it does not 
distinguish between reads from normal versus malignant Hodgkin/Reed-Sternberg cells. On the other 
hand, interim PET and CT is currently investigated as an instrument to guide therapeutic stratification 
in early response-adapted therapy.24 Our findings suggest a potential for circulating cell-free DNA 
profiling in classical Hodgkin’s lymphoma as a non-interventional instrument in staging and in early 
interim disease diagnostics as a first translational avenue.  
Analysis of circulating cell-free DNA in Hodgkin’s lymphoma might become a preferential gateway to 
the genome of the Hodgkin/Reed-Sternberg cells because it circumvents the technical difficulty of purifying 
these cells from biopsies. Although the low resolution and coverage of genomic representations profiling 
restricts its potential for biological discovery or detection of point mutations, these limitations do not 
hold for other techniques applicable to circulating cell-free DNA.9 Yet, the data from this series of ten 
patients suggest that genomic representation profiling can show heterogeneity in the patterns of genomic 
imbalances. Again, larger studies will be required to catalogue these patterns at diagnosis or relapse. 
This step will be highly relevant for translational research, as numerous signalling pathways can be 
deregulated in classical Hodgkin’s lymphoma, including the NFκB and JAK-STAT pathways, with several 
of their players—eg, REL (2p16) and JAK2 (9p24), affected by genomic gains.2,6,8,25–28 Hence, genomic 
representation profiling of circulating cell-free DNA could open up several exciting possibilities—eg, to 
investigate prospectively whether specific genomic profiles are associated with responsiveness or 
resistance to conventional Hodgkin’s lymphoma therapy,7,8 or to explore genomic evolution of 
Hodgkin/Reed-Sternberg cells between initial diagnosis and relapse. Classical Hodgkin’s lymphoma cell 
lines with 9p24/JAK2 copy gain are sensitive to JAK2 inhibition in vitro and in vivo, suggesting that clinical 
trials of JAK2 blockade are warranted.29 In this context, genomic representation profiling could be an 
attractive instrument to identify, in patients, the genomic patterns that predict the response to JAK2 
inhibitors or other new biological agents. An additional asset of genomic representation profiling in such a 
context of pretherapy testing is its turn-around time of about 1 week. UPN01 exemplifies that concurrent 
malignancies with somatically acquired genomic imbalances can confound NIPT. This patient also 
represents, to the best of our knowledge, the first in whom such discordant NIPT results led to a 
diagnosis and treatment of malignancy during gestation. In another case with discordant NIPT results, 
a metastatic cancer was diagnosed only after at term delivery, with tumoural imbalances 
corresponding with the NIPT abnormalities.30 Given a cancer incidence 25 of one per 1000–2000 
person-years in 20–40-year-old women31 and the present large-scale implementation of NIPT, one 
might wonder why no more cases have been reported to date. The NIPT focus on detection of fetal 
trisomies 13, 18, and 21 is a plausible reason,10 but cancer 30 related variables could also be involved. 
The potential detection of some maternal cancers could be seen as an added value of NIPT and specific 
software adaptations to flag potential cancer related imbalances could be useful.  
In conclusion, the presence of DNA derived from 35 Hodgkin/Reed-Sternberg cells in circulating cell-free 
DNA from classical Hodgkin’s lymphoma patients opens important new perspectives for the exploration 
of the biology and for the diagnosis and management of early and advanced classical Hodgkin’s 
lymphoma. Through facilitation of the development of long-awaited biomarkers and the design of 
clinical trials with novel biological drugs, this discovery might advance targeted and precision therapy 
in classical Hodgkin’s lymphoma. 
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Blood was obtained in Cell-Free DNA BCT® tubes (Streck, Omaha, NE), and circulating cell-
free DNA extracted from 4-5 ml of plasma. Sequencing libraries were prepared using the 
TruSeq Chip Sample preparation kit (Illumina, San Diego, CA), indexed and analyzed by 
multiplex sequencing across both lanes of an Illumina HiSeq2500 (fast mode producing 50bp 
single-end reads in pools of 23-24 samples).  
The sequence reads were aligned to the reference genome using the Burrows-Wheeler aligner, 
de-duplicated with Picard tools (http://picard.sourceforge.net/), and realigned and recalibrated 
with GATK. Reads were removed that match (sub-optimally) at multiple locations, require 
mismatches or gaps in the alignment or start in blacklisted regions taken from an in-house 
curated list of common polymorphic CNV’s, collapsed repeats, DAC blacklisted regions 
generated for the ENCODE project, and the undefined portion of the reference genome. Thus, 
minimum of 7·9x106 reads (mean 10·3x106) were obtained corresponding to a minimum of 
~11·3x106 raw reads (mean 14·5 x106)15. 
The aligned and filtered reads were counted as described. Normalization was performed with 
respect to the autosomes. We partitioned all autosomes into 50-kb bins, corrected the 
sequence counts with LOESS regression according to the bin GC content, and divided the 
result by the sum of autosomal sequence counts, yielding bin GC-corrected genomic 
representations (GR). These were aggregated per autosome and per window representing 
1/10th partitions of the chromosome, where the windows are shifting by 50kb. Z-scores for the 
genomic representation were calculated using mean and standard deviation of genomic 
representation values from a reference set of 100 normal samples (50 male (46,XY), 50 female 
(46,XX) pregnancies). Z-scores >1·5 and <-1·5 suggest gain or loss respectively 15 (for detailed 
description and references see supplementary appendix). 
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Array comparative genomic hybridization (aCGH) and FISH 
aCGH was performed with 60k CytoSure ISCA v2 microarray, and analyzed with CytoSure 
Interpret Software (Oxford Gene Technology OGT, Oxford, UK). 
FISH was performed on fixed cells from cytogenetic cultures, or on 5 µm sections of FFPE or 
snap-frozen biopsies following standard procedures. Combined FISH/CD30 immunostaining 
was done on 5 µm sections from snap-frozen biopsies. FISH images were acquired with a 
fluorescence microscope with an Axiophot2 camera (Carl Zeiss Microscopy, Jena, Germany) 
and ISIS software (MetaSystems, Altlussheim, Germany). Detailed methods and DNA probes 
are described in the Supplementary Methods and Table S1. 
 
Immunohistochemistry 
FFPE tissue sections were stained automatically (DAKO, Carpinteria, CA). Antibodies against 
Ki67 (MIB1, DAK0, Glostrup, Denmark) and against cleaved caspase-3 (Ab2302, Abcam, 
Cambridge Science Park, Boston) were used as ready to use or at 1/50 dilution respectively. 
Two expert independent observers counted Hodgkin/Reed-Sternberg cells in five 
representative high power fields each. The percentage of Ki67 positive Hodgkin/Reed-
Sternberg cells was estimated by visual interpretation of the immunohistochemical stain taking 
into account the presence of Ki67+ small lymphocytes and larger histiocytes, in correlation with 
the cellular detail and distribution of the corresponding HE stain, CD30 immunostain and the 
blue counterstain.  
 
Imaging 
Routine classical Hodgkin’s lymphoma staging and follow-up imaging was with FDG-PET/CT 
(UPN01-03, UPN06-10) and/or CT (UPN04-05)16. During pregnancy, UPN01 was evaluated by 
whole body diffusion-weighted magnetic resonance imaging, a radiation and contrast medium 
free imaging modality (clinical studies NCT00330447 and NCT01231269).17 
 
Statistical Analysis 
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Observed proportions and 95% exact (Clopper-Pearson) lower confidence limits are reported. 
Computations have been performed using the SAS statistical software package, version 9.3. 
 
Role of the funding source 
The funding sources were not involved in the study design, collection, analysis and 
interpretation of the data, or the writing of the manuscript. All authors had full access to all of 
the data. PV had the final responsibility to submit for publication. 
 
RESULTS 
Case report 
Non-invasive prenatal testing was performed on circulating cell-free DNA from a 27-year old 
asymptomatic pregnant woman UPN01 at 12 weeks gestational age and yielded a markedly 
abnormal genomic representation profile. According to local guidelines, a second circulating 
cell-free DNA sample was obtained and analyzed 2 weeks later with a similar result (Figures 1 
and 2, Figure S1), thus excluding poor quality of the sample and/or the sequencing process. 
Therefore, suspecting a biological reason for the aberrant profile, amniocentesis was performed 
followed by aCGH and conventional karyotyping on amniotic cells: both indicated a normal 
diploid fetal genome (not shown). The pregnant mother also had a normal diploid genome, as 
evidenced by aCGH on her lymphocytes (not shown). Hence, a malignant disorder in mother or 
fetus, with somatically acquired genomic imbalances, was considered. A fetal tumour was 
excluded by expert fetal ultrasound, but whole body diffusion-weighted magnetic resonance 
imaging of the mother showed a confluent anterior mediastinal mass and multiple pathologically 
enlarged lymph nodes in the left lower cervical and bilateral retroclavicular regions, without 
involvement elsewhere. A CT-guided puncture biopsy of the mediastinal mass revealed a 
NSHodgkin’s lymphoma on pathological examination. aCGH on whole DNA from the biopsy 
showed a normal diploid pattern, as expected (not shown). Therefore, in search of genomic 
imbalances in Hodgkin/Reed-Sternberg cells, we resorted to FISH analysis of FFPE biopsy 
sections. Three regions gained in the genomic representation profile, 8qter, 9pter and 14q, 
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were examined with probes for MYC (8q24), JAK2 (9p24) and IGH@ (14q32) (Figure 1). The 
JAK2 probe was applied together with a probe for centromere (CEP) 8, as ploidy control. 
Hodgkin/Reed-Sternberg cells showed 3-4 MYC signals, two CEP8 signals, 1-2 clusters of 
amplified JAK2 signals in addition to two normal signals, and four IGH signals (Table 1). In 
contrast, normal patterns were observed in neighbouring cells (Figure 1). Assuming a 
hyperdiploid status of Hodgkin/Reed-Sternberg cells in this case, the genomic gains in 
circulating cell-free DNA match with gains of the corresponding chromosomal regions in 
Hodgkin/Reed-Sternberg cells, as shown by FISH. This strongly suggests that circulating cell-
free DNA from UPN01 contains DNA representative of Hodgkin/Reed-Sternberg cells. 
 
 Genomic representation profiling of circulating cell-free DNA recurrently reveals 
genomic imbalances in NSHodgkin’s lymphoma 
We hypothesized that aberrant genomic representation profiles in circulating cell-free DNA 
could be recurrent in NSHodgkin’s lymphoma. Therefore, circulating cell-free DNA was 
prospectively obtained from cases UPN02-10, consecutively diagnosed in our hospital with 
newly diagnosed NSHodgkin’s lymphoma (UPN02-04, UPN06-10) or with NSHodgkin’s 
lymphoma in first relapse (UPN05). Seven cases had supradiaphragmatic stage IIA disease 
and two had stage IVB disease (Table 1). 
Figure 2 shows a composite plot of the diagnostic genomic representation profiles of all 
patients, including UPN01. As in case UPN01, the profiles of cases UPN03, UPN07, UPN08, 
UPN09 and UPN10 revealed marked imbalances affecting several chromosomes or 
chromosomal arms, while in cases UPN04-06 fewer and less pronounced imbalances were 
found. No obvious abnormalities were identified in case UPN02 (Figure 2, Figure S1). The most 
frequently affected regions, with gain in five or more cases, were 2p (n=7), 3q, 5p and 9p/9pter 
(n=5). Other regions with gain in 3-4 cases included 8q/8qter, chromosome 12, and 
chromosome 19 (n=4), and 1q, 2q, 5q, chromosome 14, and 17q (n=3). Loss of 1p, 6q, 7q/qter, 
9qter, 10q, 11qter, 13q and 22q were found in 4-5 cases, and loss of chromosome 4, 17p, 
chromosome 18 and 20p were each seen in three cases (Figure 2, Figure S1). 
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To verify genomic representation profiles, all Hodgkin/Reed-Sternberg cells that could be 
identified morphologically were extensively evaluated by FISH on cytogenetic specimens 
(Table 1, Figure 3). There was a striking overall concordance between genomic imbalances in 
circulating cell-free DNA and altered copy numbers of the corresponding chromosomal regions 
in nearly all FISH experiments. For instance, the genomic representation profile of UPN08 
indicated loss of 7q, and gain of 1q, 2p, 7p, and 9p (excluding 9p24). These regions were 
explored by interphase FISH on cytogenetic specimens, using probes for CKS1B (1q21)/CEP1, 
ALK (2p23), TCRG@ (7p14)/CEP7, D7S486 (7q31)/CEP7, and JAK2 (9p24)/CEP8. Giant cells 
displayed 3 CKS1B signals versus 2 CEP1 signals, 5-11 signals for ALK, and 3-4 signals for 
TCRG@ versus 2-3 CEP7 signals. They also showed 2-4 signals for D7S486 versus 4-8 CEP7 
signals. FISH thus confirmed gain of 1q, 2p and 7p and loss of 7q (Figure 3B-D and Table 1). 
To identify the cells with abnormal hybridization patterns with certainty, we combined FISH for 
2p24 (MYCN) with CD30 immunostaining on the snap-frozen biopsy of UPN08. The giant cells 
with additional 2p24/MYCN signals were CD30-positive, identifying them unequivocally as 
Hodgkin/Reed-Sternberg cells. Neighbouring cells with normal patterns were CD30-negative 
(Figure 3F). Of note, the giant cells often displayed more than two centromeric signals for 
chromosomes 1, 7 or 8: this reflects the frequently polyploid and multinucleated state of 
Hodgkin/Reed-Sternberg cells 18. In addition, several hybridization patterns in the giant cells 
were often observed within experiments, consistent with the known subclonal variation of 
Hodgkin/Reed-Sternberg cells 19: for instance, FISH for 9p24 in UPN08 showed a balanced 
pattern in three cells and gain in three others, yielding only partial concordance with the 
genomic representation profile for 9p (Figure 3E and Table 1). The small surrounding non-
malignant cells exhibited homogeneously normal hybridisation patterns.  
FISH for ALK (2p23) indicated gain in UPN03-10, while UPN02 was confirmed to have two 
copies (Table 1, Figure 3G), consistent with genomic representation profiling in all but one case 
(UPN06). For D7S486 (7q31), FISH and genomic representation profiling were concordant in 
all cases tested. For JAK2 (9p24), FISH was in agreement with genomic representation 
profiling in UPN01-03 and UPN05-08. For UPN09, partial concordance was found, again due to 
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subclonal variation (Table 1, Figure 3A, G, H). UPN04 and UPN 10 were discordant, with gain 
in FISH despite, respectively, a balance or loss in the genomic representation profile for 
9p/9pter (Table 1). Hence, with only three discordances in total, we find a striking overall 
agreement between the genomic imbalances in circulating cell-free DNA by genomic 
representation profiling and those in Hodgkin/Reed-Sternberg cells found by FISH. This 
cogently proves that circulating cell-free DNA contains DNA derived from and representative of 
Hodgkin/Reed-Sternberg cells. 
 genomic representation profile aberrations were most pronounced in cases UPN08-09, each 
with stage IVB disease. This suggests a correlation between tumour load and Hodgkin/Reed-
Sternberg cell-derived DNA in the circulating cell-free DNA. Nevertheless, genomic 
representation profiling also allowed detection of several aberrations in UPN03-07 and UPN10 
with NSHodgkin’s lymphoma stage IIA, although some gains (2p23 in UPN06, and 9p24 in 
UPN04 and UPN10) were not correctly identified (Table 1). Based on eight positive results out 
of nine prospectively recruited cases, the 95% lower limit for the proportion of positive samples 
equals 57%: thus implying strong evidence for abnormal circulating cell-free DNA profiles in a 
considerable proportion of NSHodgkin’s lymphoma cases. 
 
Normal genomic representation profiles are restored upon initiation of antineoplastic 
therapy 
All patients, including the pregnant patient, were treated with ABVD chemotherapy with or 
without involved node radiotherapy, except UPN04-05 who were treated according to EuroNet-
PHodgkin’s lymphoma recommendations. All responded as shown by early clinical evaluation. 
At the first interim PET/CT imaging evaluation after 2-4 cycles of chemotherapy, patients 
UPN01-04 and UPN06-10 all had reached complete metabolic remission. Patient UPN05 
reached partial remission at the first interim evaluation by CT evaluation after 4 cycles and 
complete metabolic remission by PET/CT at the completion of chemotherapy. The 
abnormalities in the genomic representation profile at diagnosis were no longer observed in 
subsequent samples taken between day 15-43 after treatment initiation (Figure 4, Figure S2). 
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This, in combination with the clinical disease response, further underscores the link between 
the abnormal genomic representation profiles and the malignant process and its burden. 
Furthermore, it suggests that early responses can be monitored non-invasively. 
 
Cell proliferation, apoptosis and necrosis in NSHodgkin’s lymphoma 
The ease by which Hodgkin/Reed-Sternberg DNA is detectable in circulating cell-free DNA 
contrasts with the paucity of Hodgkin/Reed-Sternberg cells in classical Hodgkin’s lymphoma 
biopsies. We hypothesized that high Hodgkin/Reed-Sternberg turnover rates could be a key 
factor underlying this paradox. In general, Hodgkin/Reed-Sternberg cells showed bright nuclear 
expression of the cell cycle indicator Ki67 in all 10 cases, with immunoreactivity ranging 
between 30-90% (median 77%) of Hodgkin/Reed-Sternberg cells in individual cases. In 
addition to morphological signs of apoptosis, immunoreactivity with the anti-cleaved caspase-3 
antibody was observed in a fraction of Hodgkin/Reed-Sternberg cells in 6/10 biopsies. Of note, 
areas of tissue necrosis were observed in two of 10 biopsies. Representative images are 
shown in Figure 5. 
 
DISCUSSION 
The scarcity of Hodgkin/Reed-Sternberg cells in classical Hodgkin’s lymphoma biopsies has for 
a long time defied the identification of recurrent genetic lesions in classical Hodgkin’s 
lymphoma, including NSHodgkin’s lymphoma.2-8 Here, we report proof-of-principle that genomic 
imbalances in Hodgkin/Reed-Sternberg cells can be profiled at diagnosis by massive parallel 
sequencing of circulating cell-free DNA in the majority of cases with early and advanced stage 
NSHodgkin’s lymphoma.  
Of note, elevated levels of circulating cell-free DNA were previously reported in classical 
Hodgkin’s lymphoma, and correlated with unfavorable features. However, the origin of this 
circulating cell-free DNA was not further investigated20,21. This study is, to the best of our 
knowledge, the first to demonstrate that genomic imbalances of Hodgkin/Reed-Sternberg cells 
can be detected in circulating cell-free DNA. The straightforward identification in circulating cell-
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free DNA of genomic imbalances in Hodgkin/Reed-Sternberg cells is unexpected but 
welcomed, in that retrieving genetic information on Hodgkin/Reed-Sternberg cells from 
Hodgkin’s lymphoma biopsies is notoriously demanding from a technical point of view. Indeed, 
the current knowledge on the genetics of Hodgkin/Reed-Sternberg cells is almost entirely 
derived from a small number of studies of Hodgkin’s lymphoma cell lines, and of 
microdissected Hodgkin/Reed-Sternberg cells, after whole genome DNA amplification4-8. 
Reassuringly, the imbalances identified in this study of ten NSHodgkin’s lymphoma are already 
known from aCGH studies on microdissected Hodgkin/Reed-Sternberg cells, albeit with 
different frequencies.4-8 Interestingly, we also confirm that 2p gain and 6q loss often occur 
together8. We also found gain of 16p11-13, previously identified in 25% of classical Hodgkin’s 
lymphoma, and associated with therapy resistance8, in two cases with stage IVB. The presence 
of informative amounts of Hodgkin/Reed-Sternberg cell derived DNA in circulating cell-free 
DNA, despite their scarcity in classical Hodgkin’s lymphoma biopsies, probably implies that 
Hodgkin/Reed-Sternberg cells are subject to a higher cellular turnover rate than previously 
anticipated. Although we studied one proliferative and one apoptotic marker only, their 
coexpression on Hodgkin/Reed-Sternberg cells and the presence of necrosis in classical 
Hodgkin’s lymphoma biopsies seem to support the notion that active proliferation is 
counterbalanced by high rates of Hodgkin/Reed-Sternberg cell loss by apoptosis or necrosis, in 
keeping with expression studies in Hodgkin/Reed-Sternberg cells.22,23 This delicate balance 
might also explain the high cure rates of chemotherapy, as Hodgkin/Reed-Sternberg cells are 
already poised for cell death. 
 genomic representation profiles were most markedly abnormal in in the two patients (UPN08-
09) with advanced disease, suggesting a correlation between the Hodgkin/Reed-Sternberg cell 
burden and the level of Hodgkin/Reed-Sternberg cell derived DNA in circulating cell-free DNA. 
However, seven of eight cases with early stage IIA (including patient UPN01) had abnormal 
profiles too. Based on the high proportion of abnormal genomic representation profiles in this 
small series, a substantial, if not the major, proportion of cases with NSHodgkin’s lymphoma is 
expected to have abnormal circulating cell-free DNA profiles. Larger studies are needed to 
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precisely determine the sensitivity of this technique in classical Hodgkin’s lymphoma, in relation 
with the disease stage. These larger studies should also include the mixed cellularity, 
lymphocyte-rich and lymphocyte-depleted subtypes of classical Hodgkin’s lymphoma, and 
nodular lymphocyte predominant Hodgkin’s lymphoma, less common types of Hodgkin’s 
lymphoma which were not included in this study.  
The relation between Hodgkin/Reed-Sternberg cell burden and the abnormal genomic 
representation profile is also underscored by the rapid clearance of genomic representation 
abnormalities present at diagnosis after the initiation of therapy. Given this rapid clearance, 
genomic representation profiling seems unlikely to have significant potential to sensitively 
monitor low levels of residual disease, even more so as it does not distinguish between reads 
from normal versus malignant Hodgkin/Reed-Sternberg cells. On the other hand, interim 
PET/CT is currently investigated as a tool guiding therapeutic stratification in early response-
adapted therapy 24. Our findings suggest a potential for circulating cell-free DNA profiling in 
classical Hodgkin’s lymphoma as a non-interventional tool in staging and in early interim 
disease diagnostics as a first translational avenue.  
Analysis of circulating cell-free DNA in Hodgkin’s lymphoma might become a preferential 
gateway to the genome of the Hodgkin/Reed-Sternberg cells, as it circumvents the technical 
difficulty of purifying these cells from biopsies. While the low resolution and coverage of 
genomic representation profiling limit its potential for biological discovery or detection of point 
mutations, these limitations do not hold for other techniques applicable on circulating cell-free 
DNA 9. Yet, the data from this series of ten patients suggest that genomic representation 
profiling can reveal heterogeneity in the patterns of genomic imbalances. Again, larger studies 
will be required to catalogue these patterns at diagnosis and/or relapse. This will be highly 
relevant for translational research, as numerous signaling pathways can be deregulated in 
classical Hodgkin’s lymphoma, including the NFκB and JAK-STAT pathways, with several of 
their players, e.g. REL (2p16) and JAK2 (9p24), affected by genomic gains 2,6,8,25-28. Hence, 
genomic representation profiling of circulating cell-free DNA could open up several exciting 
possibilities, e.g. to investigate prospectively whether specific genomic profiles are indeed 
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associated with resistance to conventional Hodgkin’s lymphoma therapy,7,8 or to explore 
genomic evolution of Hodgkin/Reed-Sternberg cells between initial diagnosis and relapse. 
classical Hodgkin’s lymphoma cell lines with 9p24/JAK2 copy gain are sensitive to JAK2 
inhibition in vitro and in vivo, suggesting that clinical trials of JAK2 blockade are warranted 29. In 
this context, genomic representation profiling could be an attractive tool to identify, in patients, 
the genomic patterns that predict the response to JAK2 inhibitors or other new biological 
agents. An additional asset of genomic representation profiling in such a context of pretherapy 
testing is its turn-around-time of about one week. 
UPN01 exemplifies that concurrent malignancies with somatically acquired genomic 
imbalances can confound Non-invasive prenatal testing. She also represents, to the best of our 
knowledge, the first patient in whom such discordant Non-invasive prenatal testing results led 
to a diagnosis and treatment of malignancy during gestation. In another case with discordant 
Non-invasive prenatal testing results, a metastatic cancer was diagnosed only after at term 
delivery, with tumoural imbalances corresponding with the Non-invasive prenatal testing 
abnormalities.30 Given a cancer incidence of 1 per 1000-2000 person-years in 20-40 year old 
women31 and the present large scale implementation of Non-invasive prenatal testing, one may 
wonder why no more cases have been reported to date. The Non-invasive prenatal testing 
focus on detection of fetal trisomies 13, 18 and 21 is a plausible reason,10 but cancer related 
variables could also be involved. The potential detection of some maternal cancers could be 
seen as an added value of Non-invasive prenatal testing and specific software adaptations to 
flag potential cancer related imbalances could be useful. 
In conclusion, the presence of DNA derived from Hodgkin/Reed-Sternberg cells in circulating 
cell-free DNA from classical Hodgkin’s lymphoma patients opens important new perspectives 
for the exploration of the biology and for the diagnosis and management of early and advanced 
classical Hodgkin’s lymphoma. Through facilitation of the development of long-awaited 
biomarkers and the design of clinical trials with novel biological agents, this discovery may 
advance targeted and precision therapy in classical Hodgkin’s lymphoma.  
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FIGURES AND FIGURE LEGENDS 
Figure 1. genomic representation profile and FISH analysis of selected chromosomes of 
patient UPN01. 
The left of each panel shows a chromosomal genomic representation profile with z-scores 
(horizontal axis) in relation to the chromosomal position (vertical axis, aligned with the 
chromosomal idiogram). The area under the curve is shown in blue for z-scores > 1·5 
(suggesting gain) and in red for z-scores <-1·5 (suggesting loss). On the right of each panel, 
representative FISH images of interphase nuclei, including one giant RS cell (white arrow) and 
several other small interphase cells, are shown. The arrow on the idiogram indicates the 
chromosomal location of the home-made or LSI probe used 
A-B. Chromosome 9 with gain of 9p24 (arrow). FISH probes: home-made JAK2 break-apart 
(red/green) (9p24) and CEP8 (blue). Both images were captured using a 
DAPI/FITC/SpectrumOrange/DEAC-band pass filter, but image B is shown in inverted gray 
scale to visualize blue (Spectrum Aqua) CEP8 signals. 
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C. Chromosome 8 with gain of 8q24 (arrow). FISH probe: LSI MYC break apart (red/green) 
(8q24) 
D. Gain of chromosome 14 (arrow). FISH probe: LSI IGH@ break-apart (red/green) (14q32). 
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Figure 2. genomic representation profiles of cases UPN01-10. 
The circos plot shows the genomic representation profile of the autosomal chromosomes in 
clockwise order, aligned with chromosomal idiograms (outer circle). UPN01-10 are shown from 
the periphery to the center. Z-scores >1·5 (suggesting gain) are shown in blue, and z-scores < -
1·5 (suggesting loss) in red, where darker colors represent higher absolute values of z-scores. 
Z-scores between -1·5 and +1·5 are shown in yellow. Seven color grades are used to indicate 
six z-score intervals of length 0·75 ranging from 1·5 (-1·5) to 6 (-6). The seventh, darkest color 
is reserved for values >6 or <-6. 
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Figure 3. genomic representation profile and FISH analysis of selected chromosomes of 
patients UPN07-10. 
The genomic representation profile of selected chromosomes is shown at the left of each panel, 
aligned with the corresponding idiograms .The area under the curve is in blue for z-scores > 
1·5 and in red for z-scores <-1·5. Note that the scale of the horizontal axis varies between 
patients. To the right of each panel, a representative interphase FISH image is shown. The 
arrow on the idiogram indicates the chromosomal location of homebrew or LSI probes used. 
A. UPN07. genomic representation profile of chromosome 9. Interphase FISH image of a giant 
Hodgkin/Reed-Sternberg cell and a small non-Hodgkin/Reed-Sternberg cell, confirming 
amplification of JAK2 (9p24) (red/green) in the giant cell relative to CEP8 (blue). 
B. UPN08. genomic representation profile of chromosome 1. Interphase FISH image of a giant 
Hodgkin/Reed-Sternberg cell, confirming gain of CKS1B (1q21) (green) over CEP1 (red). 
C. UPN 08. genomic representation profile of chromosome 7. Interphase FISH image of a giant 
Hodgkin/Reed-Sternberg cell and a small non-Hodgkin/Reed-Sternberg cell, confirming gain of 
TCRG@ (7p14) (red/green) over CEP7 (green) in the Hodgkin/Reed-Sternberg cell. 
D. UPN 08. genomic representation profile of chromosome 7. Interphase FISH image of a giant 
Hodgkin/Reed-Sternberg cell and a small non-Hodgkin/Reed-Sternberg cell confirming loss of 
D7S486 (7q31) (red) relative to CEP7 (green) in the Hodgkin/Reed-Sternberg cell. 
E. UPN08. genomic representation profile of chromosome 9, with gain of 9p, but not including 
9p24 (arrow). Interphase FISH image of a giant Hodgkin/Reed-Sternberg cell with 2 signals for 
JAK2 (9p24) (red/green) and centromere 8. 
F. UPN08. genomic representation profile of chromosome 2. Image of combined FISH for 
MYCN (2p24) (red) and immunostaining for CD30 (green). The giant cell with 5 signals for 
MYCN is immunoreactive with anti-CD30, in contrast with the surrounding cells with two 
hybridization signals. 
G. UPN09. GR profile of chromosome 2. Interphase FISH image of a giant Hodgkin/Reed-
Sternberg cell with amplification of ALK (2p23) (red/green). 
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H. UPN10. genomic representation profile of chromosome 7. Interphase FISH image of a giant 
Hodgkin/Reed-Sternberg cell, confirming loss of D7S486 (7q31) (red) relative to CEP7 (green). 
 
 
Figure 4. genomic representation profiles before and after treatment initation. 
Circos plots show GR profiles of the autosomal chromosomes in clockwise order, aligned with 
chromosomal idiograms (outer circle), before therapy and after therapy initiation for UPN01, 
UPN03, UPN 07-10. The pretherapy genomic representation profile is shown as the outer 
circle, while the inner circle(s) show(s) genomic representation profiles after therapy initiation. 
The samples after treatment initiation were obtained at the following time points : UPN01: day 
15; UPN03: day 15; UPN 07: day 43; UPN08: day 29; UPN09: day 15 (middle circle) and day 
29 (inner circle); UPN10 (day 29). Z-scores >1·5 (suggesting gain) are shown in blue, and z-
scores < -1·5 (suggesting loss) in red, where darker colors represent higher absolute values of 
z-scores. Z-scores between -1·5 and +1·5 are shown in yellow. Seven color grades are used to 
indicate six z-score intervals of length 0.75 ranging from 1·5 (-1·5) to 6 (-6). The seventh, 
darkest color is reserved for values >6 or <-6. 
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Figure 5. Areas of necrosis, expression of Ki67 and presence of cleaved caspase-3 in NS 
Hodgkin’s lymphoma. 
A. Low power view of architectural effacement of lymph node involved by classical Hodgkin 
lymphoma, including areas of necrosis (n) (Hematoxylin Eosin); 
B. High power view of neoplastic Hodgkin/Reed-Sternberg-cells in a background of non-
neoplastic stromal cells, containing lymphocytes, eosinophils, neutrophils, plasmacells and 
histiocytes (Hematoxylin Eosin). 
C. Hodgkin/Reed-Sternberg-cells show a high proliferation index (anti-Ki67/Mib1 
immunostaining); 
D. Hodgkin/Reed-Sternberg-cells show signs of apoptosis, with karyorrhexis (see inset) and/or 
cytoplasmic expression of cleaved Caspase-3 (anti-cleaved caspase-3 HRP immunostaining); 
Arrows indicate Hodgkin/Reed Sternberg cells (Hodgkin/Reed-Sternberg); scalebar: 50µm 
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a   Cytogenetics : in case UPN05 and 06, one and two abnormal metaphases were identified respectively, indicating a pseudotriploid status of the 
Hodgkin/Reed‐Sternberg cell. ND: not done. NM: no metaphases 
b   Status of the indicated region as analyzed by genomic representation profiling 
TABLE 1
2p 7q 9p/9pter other
GRb FISHc concordant d GRb FISHc concordant d GRb FISHc concordant d GRb FISHc con
Case Sex/
age (y)
Stage ALK (2p23)
#signals[#cells]     
D7S486 (7q31)
/CEP7
#signals[#cells]
JAK2 (9p24)
/CEP8
#signals[#cells]
probe (region):
#signals[#cells]
UPN01 F/27 IIA ND normal ND - normal ND - gain amp/2[11] Y
8qter gain
chr.14 
gain
MYC (8q24): 3-6[7]
IGH@ (14q32): 4-5[7]
UPN02 F/65 IIA NM normal 2[2] Y normal ND - normal 2/2[3] Y -
UPN03 F/21 IIA ND gain 2[2]; 4[4]; 5[1]; 13[1] Y loss 2/4[1]; 3/6[1]; 5/6[1] Y gain
4/2[1]; 5/2[1]; 
6/1-3[3]; 7/1-4[2]; 
8/2-3[2]; 9/2[1]
Y -
UPN04 F/12 IIA NM gain 2[1]; 6[1], 
8[2],amp[7]
Y loss 3/4[2]; 3/5[3]; 5/7[2]; 
7/8[1]
Y
gain 9p/    
normal 
9p24
4/2[1]; 4/4[1]; 6/2[1]; 
6/4[3]; 7/2[1]; 8/5[1]
N -
UPN05 F/17 IIA abnormal gain 4[4]; 5[5] Y normal 4/4[10] Y loss ? 2/3[9] Y
UPN06 F/18 IIA abnormal normal 4[3] N normal ND - gain 5/3[3]; 5/4[1]; 7/3[2] Y
UN07 M/30 IIA 46,XY[1] gain 3[1]; 4[2]; 5[3]; 7[1]; 
8[1]; 13[1]
Y normal ND - gain
9/4[1]; 9/5[1]; 
10/5[1]; 10/7[1]; 
11/5[1]
Y -
UPN08 M/26 IVB 46,XY[3] gain 5[2]; 6[3]; 7[1]; 
10[1]; >10[1]
Y loss 2/4[1]; 4/8[1] Y
gain 9p/    
normal 
9p24
2/2[1]; 3/3[2];  
5/3[1]; 7/3[1]; 7/6[1]
P
1q gain
7p gain
CKS1B (1q21)/CEP1: 
3/2[3]; 6/4[1]
TCRG@ (7p14)/CEP7: 
4/3[3]
UPN09 M/39 IVEB NM gain 5[1]; 6[2]; 7+amp[1] Y loss
1/2[1]; 1/4[1]; 3/4[1]; 
3/5[1]; 5/7[1]; 6/9[1]; 
8/15[1]
Y normal 3/4[1]; 4/4[1]; 5/3[1]; 
6/9[1]
P
UPN10 F/45 IIA 46,XX[20] gain 4[12]; 5[1]; 8[1]; 
10[1]
Y loss 2/3[5] Y loss 3/3[7]; 6/4[1];9/5[1] N
Cytogeneticsa
Recurrent imbalances suggested by GR profiling and validated by interphase FISH 
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c   FISH was performed with the probes indicated. Giant Hodgkin/Reed‐Sternberg cells were evaluated. Hybridization patterns of Hodgkin/Reed‐Sternberg 
cells are shown, followed by the number of Hodgkin/Reed‐Sternberg cells with the given pattern between square brackets. Different hybridization patterns are 
separated by ";". ND: not done 
d   Concordance between FISH and genomic representation profiling. Y: yes. N: no. P: partial 
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RESEARCH IN CONTEXT 
Systematic review :  
We searched PubMed for articles on cell‐free DNA and Hodgkin lymphoma or non‐Hodgkin lymphoma, 
excluding Epstein‐Barr virus. This retrieved only two articles indicating that increased levels of 
circulating cell‐free DNA can be found in non‐Hodgkin and Hodgkin lymphoma, and correlate with 
adverse features. Whether this circulating cell‐free DNA originated from malignant versus non‐
malignant cells was not investigated. 
We also searched PubMed for articles with “Hodgkin lymphoma” and “genome, genetics, mutations, 
chromosome or cytogenetics” (in the title or abstract), excluding non‐Hodgkin lymphoma and Nodular 
lymphocyte predominant Hodgkin Lymphoma. This search retrieved 35‐45 relevant research articles 
published between 1993 and present. These papers studied either Hodgkin Lymphoma derived cell‐
lines, cultured cells from Hodgkin Lymphoma biopsies, Hodgkin/Reed‐Sternberg cells identified by 
immunohistochemistry in biopsies, or Hodgkin‐Reed/Sternberg cells purified by laser microdissection or 
flow cytometry from Hodgkin Lymphoma biopsies. The methods used were cytogenetics, FICTION ( a 
combination of FISH and immunohistochemistry), array comparative genomic hybridization, gene‐
expression profiling or mutational analysis.  
Interpretation 
This is the first report that genetic features of Hodgkin/Reed‐Sternberg cells in classical Hodgkin 
Lymphoma can be revealed by analysis of cell‐free circulating DNA. Given the technical difficulty to 
analyse the genetics of primary Hodgkin/Reed‐Sternberg cells in biopsies, analysis of circulating cell‐
free DNA may open up new translational avenues for the development of biomarkers and of precision 
medicine in classical Hodgkin lymphoma.  
 
 
